Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDP-120 is a fixed-dose combination topical gel developed for the treatment of moderate to severe acne vulgaris. The formulation consists of two components, with "Component B" specifically referring to one part of this admixture. According to patent documentation, IDP-120 is an admixture by weight of two components; however, the precise composition of "Component B" is not explicitly detailed in public sources. The overall product (IDP-120) contains benzoyl peroxide and tretinoin as active ingredients[6][7]. Benzoyl peroxide acts as an antibacterial and keratolytic agent, while tretinoin is a retinoid that modulates epithelial cell growth and differentiation. The mechanism involves reducing Propionibacterium acnes colonization, decreasing inflammation, and promoting skin cell turnover.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IDP-120 Component B.